Zoledronic acid
【Product name】Zoledronic, RECLAST, ZOMETA
[English common name]Zoledronic
[Chinese common name]Zoledronic acid
[English name]
[Chinese other name]
[Indications] in combination with standard anti-tumor drug therapy for the treatment of patients with solid tumor bone metastases andMultiple myelomaThe patient's bone damage. It is used to treat hypercalcemia (HCM) caused by malignant tumors.
[Usage and Dosage] This product should not be used in combination with an infusion solution containing calcium or other divalent cations (such as lactated Ringer's solution). A single intravenous infusion should be performed using an infusion tube separate from other drugs.
Adult and elderly
The recommended dose is 4 mg. Dilute with 100 ml of 0.9% sodium chloride or 5% dextrose solution for an intravenous infusion of not less than 15 minutes (see [Precautions]).
For patients with HCM (albumin-corrected serum calcium ≥ 3.0 mmol/l or 12 mg/dl), a single infusion should be accepted. Albumin-corrected serum calcium (mg/dL) = patient serum calcium (mg/dL) + 0.8 x [median serum albumin (g/L) - patient serum albumin (g/L)].
There is limited experience with re-treatment of hypercalcemia. Re-treatment must be at least 7-10 days apart from the previous one, and serum creatinine levels should be monitored before treatment.
The hydration status of the patient must be tested prior to administration and should be administered according to the clinical condition of the patient.
For patients with bone metastases and multiple myeloma, this product should be given every 3-4 weeks. In addition, patients should take 500 mg of calcium and 400 IU of vitamin D daily.
Renal insufficiency
HCM
For patients with HCM with severe renal impairment, the risk-benefit ratio needs to be assessed before considering the use of this product for treatment. In previous clinical trials, patients with serum creatinine >400 umol/l or >4.5 mg/dl were not enrolled. HCM patients with serum creatinine <400umol/l or <4.5mg/dl do not need to adjust the dose.
Patient who has developed bone metastasis
For patients with multiple myeloma and solid tumors that have undergone bone metastases, serum creatinine and creatinine clearance (CrCl) are measured at the start of treatment with this product. The CrCl value was calculated from the serum creatinine concentration value using the Cockcroft-Gault formula. Before using Zetai drugs for treatment, if the patient has developed severe renal insufficiency symptoms (CrCl<30ml/min), it is recommended to give Zetai drugs according to the following dosages (see [Precautions]): CrCl>60ml /min: 4.0 mg; CrCl 50-60 ml/min: 3.5 mg; CrCl40-49 ml/min: 3.3 mg; CrCl30-39 ml/min: 3.0 mg.
This dose was calculated based on the assumed AUS target value of 0.66 (mgxhr/l) (CrCl = 75 ml/min). The purpose of using this dose reduction method is to achieve the same AUC value for patients with renal insufficiency as patients with creatinine clearance of 75 ml/min.
After starting the medication, the serum creatinine concentration of the patient is measured before each administration of the product. Once the patient's renal function is found to be deteriorating, medication withdrawal is required. In clinical trials, the definition of deterioration of renal function is this:
Serum creatinine concentrations increased from baseline normal (dl) to ≥0.5 mg/dl; and serum creatinine concentrations increased from baseline outliers (>1.4 mg/dl) to >1.0 mg/dl.
In clinical studies, treatment of this product is continued only when creatinine levels are restored to within 10% of the baseline value (see [Precautions]). The dose of drug used to re-use Zetai should be the dose of the drug used in the previous treatment interruption.
Hepatic insufficiency
Because of the limited clinical data on patients with severe hepatic insufficiency, there are no specific recommendations for such patients.
Child medication
The safety and effectiveness of this product for children and adolescents has not yet been established.
[Storage]Store below 30 °C.
[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
name
Attention: The internal data of table “912” is corrupted!
product
Attention: The internal data of table “913” is corrupted!
Related products
-
Multiple myeloma , Lymphoma
Lenalidomide
【Product name】Revlimid
[English common name]Lenalidomide
[Chinese common name]Lenalidomide
[English name]Lenalidomide
[Chinese other name]Laminamide
[Indications] This product is combined with dexamethasone to treat at least one therapy.Multiple myelomaAdult patient.
【Dosage】
Treatment medication must be initiated and provided under the supervision of a physician with multiple myeloma treatment experience.
If the patient's absolute neutrophil count (ANC) is <1.0×109/L, or the patient's platelet count is <50×109/L, and the proportion of plasma cells in the bone marrow is less than 50%, or the patient's platelets Counting <30×109/L, and the ratio of plasma cells to nucleated cells in the bone marrow is >50%, then the treatment of this product should not be started.
Recommended dose
The recommended starting dose for this product is 25mg. On the 1st to 21st days of each repeated 28-day cycle, 25 mg of this product was orally administered daily until the disease progressed. The recommended dose of dexamethasone is oral administration of 40 mg of dexamethasone on days 1, 8, 15, and 22 of the 28-day treatment cycle.[Storage] Store at 20 ° C – 25 ° C (68 ° F – 77 ° F); allow for offset 15 ° C – 30 ° C (59 ° F – 86 ° F).
[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
-
Multiple myeloma , Acute leukemia
mercaptopurine
【Product name】Xaluprine, Purixan
[English common name]Mercaptopurine
[Chinese common name]mercaptopurine
[English name]LEUKERIN
[Chinese other name]Le Yunning
[Indications] for chorionic epithelial cancer,Malignant mole,Acute lymphoblastic leukemiaAnd acute nonlymphocytic leukemia,Chronic myeloid leukemiaThe urgency period.
【Dosage】
Oral administration:
Chorionic epithelial cancer: commonly used in adults, daily 6mg ~ 6.5mg / kg, divided into two oral, 10 days for a course of treatment, intermittent treatment for 3 to 4 weeks.
leukemia:
Start, daily 2.5mg / kg or 80 ~ 100mg / m2, once a day or in divided doses, generally 2 to 4 weeks after treatment can be markedly effective, such as 4 weeks after medication, no clinical improvement and white blood cell count , can be considered to be added to the daily 5mg / kg under careful observation;
Maintain, daily 1.5mg ~ 2.5mg / kg or 50mg ~ 100mg / m2, once a day or divided into oral.[Storage] Closed light, sealed storage.
[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
-
Multiple myeloma
Bortezomib
【Product name】VELCADE
[English common name]Bortezomib
[Chinese common name]Bortezomib
[English name]Dpba, Boronic acid, Bortizomib, Bortezomib for research
[Chinese other name]Botsomomi
[indications]
1. This product is used forMultiple myelomaThe patient's treatment, this patient has received at least two treatments before using this product, and the disease is still progressing in the latest treatment.
2. This product is used for recurrence or refractoryMantle cell lymphomaPatient's treatment, this patient has received at least one treatment before using this product. The safety and efficacy data for this indication comes from a single-arm phase II clinical study of a mantle cell lymphoma that has relapsed after previous treatment. There is still a lack of clinical research for the Chinese population.【Dosage】
1. Recommended dose for adult monotherapy This product is recommended for a single injection of 1.3 mg/m2, twice a week for 2 weeks (ie, on days 1, 4, 8 and 11). Days (ie from the 12th to the 21st day). 3 weeks is a course of treatment, and the two doses are at least 72 hours apart. For more than 8 courses of maintenance treatment, it can be administered according to standard protocols, or once a week, for 4 weeks of continuous maintenance (days 1, 8, 15 and 22), followed by a 12-day rest Period (22nd to 25th days).
2. Dose adjustment and restart treatment when it occurs. This grade should be discontinued when non-hematologic or any grade 4 hematologic toxicity (excluding neuropathy discussed below).[Storage] sealed and stored.
[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
-
Breast cancer , Late childhood neuroblastoma
Melphalan
【Product name】Alkeran
[English common name]Melphalan
[Chinese common name]Melphalan
[English name]Melphalan HCl, Melphalan 2HCl, l-phenylalanine mustard
[Chinese other name]Melfal, Melphalan, cancer Kyan, Milfair
[Indications] This product can be used with a variety of tumors, in single chemotherapy and combination chemotherapy,Multiple myelomaThe drug of choice. CorrectSpermato cell tumor,Breast cancer,Ovarian cancer,Chronic leukemia,Polycythemia vera,Malignant lymphoma,Late childhood neuroblastoma,Thyroid cancereffective. Arterial infusion for the treatment of limb malignancies such as malignant melanoma, soft tissue sarcoma and osteosarcoma has a good effect, even for the treatment of certain autoimmune diseases and to prevent rejection during organ transplantation.
【Dosage】
Multiple myeloma:
A typical dose is 0.15 mg per kilogram of body weight per day, taken in four divided doses, and repeated for six weeks. Prolonged treatment for those who respond to treatment will not change the effect. The combination of melphalan and prednisone may be more effective than single use.
Ovarian adenocarcinoma:
A typical treatment regimen is 0.2 mg per kilogram of body weight per day for five days, repeated every 4 to 8 weeks or when the peripheral blood is restored; the dose should be reduced when bone marrow toxicity occurs.
Advanced breast cancer:
Oral melphalan daily 0.15 mg per kilogram of body weight or 6 mg per square meter of body surface area for a total of 5 days, repeated treatments every six weeks, can also be treated with intravenous melphalan.
True erythrocytosis:
Induction of remission, use 6 to 10 mg daily for 5 to 7 days, then 2 to 4 mg per day until the symptoms can be satisfactorily controlled. The maintenance dose can be 2 to 6 mg per week. Care must be taken during the patient. The hematology control is performed on the ground, and the dose is appropriately adjusted based on the blood cell count result.
Patients with renal insufficiency:
Based on current pharmacokinetic data, oral melphalan is not recommended for patients with moderate to severe renal insufficiency, but the initial dose should be carefully reduced.[Storage]Store in a dark, cool, dry place.
[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
简体中文